Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011, Article ID 216298, 8 pages
http://dx.doi.org/10.4061/2011/216298
Review Article

Transcriptional Factor NF- 𝜅 B as a Target for Therapy in Parkinson's Disease

1Department of Periodontology and the Comprehensive Center for Inflammatory Disorders, University of North Carolina, Chapel Hill, NC 27599-7454, USA
2Department of Pharmacology and Key Lab of Pharmacology of Guizhou, Zunji Medical College, Zunji, China
3Neuropharmacology Section, Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA

Received 10 November 2010; Accepted 21 February 2011

Academic Editor: Fernando Pitossi

Copyright © 2011 Patrick M. Flood et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. L. Block and J. S. Hong, “Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism,” Progress in Neurobiology, vol. 76, no. 2, pp. 77–98, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. L. Bartels and K. L. Leenders, “Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [C]-PK11195 PET,” Movement Disorders, vol. 22, no. 13, pp. 1852–1856, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. W. Dauer and S. Przedborski, “Parkinson's disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. H. M. Gao and J. S. Hong, “Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression,” Trends in Immunology, vol. 29, no. 8, pp. 357–365, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. P. L. McGeer, S. Itagaki, B. E. Boyes, and E. G. McGeer, “Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains,” Neurology, vol. 38, no. 8, pp. 1285–1291, 1988. View at Google Scholar · View at Scopus
  6. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari, “Changes in cytokines and neurotrophins in Parkinson's disease,” Journal of Neural Transmission, no. 60, supplement, pp. 277–290, 2000. View at Google Scholar · View at Scopus
  7. M. Mogi, M. Harada, T. Kondob et al., “Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients,” Neuroscience Letters, vol. 180, no. 2, pp. 147–150, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Ouchi, S. Yagi, M. Yokokura, and M. Sakamoto, “Neuroinflammation in the living brain of Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. S200–S204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. G. A. Qureshi, S. Baig, I. Bednar, P. Sodersten, G. Forsberg, and A. Siden, “Increased cerebrospinal fluid concentration of nitrite ire Parkinson's disease,” NeuroReport, vol. 6, no. 12, pp. 1642–1644, 1995. View at Google Scholar · View at Scopus
  10. S. Hunot, F. Boissière, B. Faucheux et al., “Nitric oxide synthase and neuronal vulnerability in Parkinson's disease,” Neuroscience, vol. 72, no. 2, pp. 355–363, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Qian and P. M. Flood, “Microglial cells and Parkinson's disease,” Immunologic Research, vol. 41, no. 3, pp. 155–164, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. K. McCoy and M. G. Tansey, “TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease,” Journal of Neuroinflammation, vol. 5, article 45, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. Jenner, “Oxidative mechanisms in nigral cell death in Parkinson's disease,” Movement Disorders, vol. 13, supplement 1, pp. 24–34, 1998. View at Google Scholar · View at Scopus
  14. J. Zielasek and H. P. Hartung, “Molecular mechanisms of microglial activation,” Advances in Neuroimmunology, vol. 6, no. 2, pp. 191–222, 1996. View at Google Scholar · View at Scopus
  15. J. Rogers and L. F. Lue, “Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease,” Neurochemistry International, vol. 39, no. 5-6, pp. 333–340, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. T. C. Frank-Cannon, T. Tran, K. A. Ruhn et al., “Parkin deficiency increases vulnerability to inflammation-related nigral degeneration,” Journal of Neuroscience, vol. 28, no. 43, pp. 10825–10834, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. D. Reynolds, J. G. Glanzer, I. Kadiu et al., “Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease,” Journal of Neurochemistry, vol. 104, no. 6, pp. 1504–1525, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. E. C. Hirsch, S. Hunot, and A. Hartmann, “Neuroinflammatory processes in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 11, no. 1, pp. S9–S15, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. H. Wilms, L. Zecca, P. Rosenstiel, J. Sievers, G. Deuschl, and R. Lucius, “Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications,” Current Pharmaceutical Design, vol. 13, no. 18, pp. 1925–1928, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. P. L. McGeer, C. Schwab, A. Parent, and D. Doudet, “Presence of reactive microglia in monkey Substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration,” Annals of Neurology, vol. 54, no. 5, pp. 599–604, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. F. Cicchetti, A. L. Brownell, K. Williams, Y. I. Chen, E. Livni, and O. Isacson, “Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging,” European Journal of Neuroscience, vol. 15, no. 6, pp. 991–998, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Meissner, C. Prunier, D. Guilloteau, S. Chalon, C. E. Gross, and E. Bezard, “Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease,” Molecular Neurobiology, vol. 28, no. 3, pp. 209–218, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. D. Ebert, J. H. Hoo, and M. C. Bohn, “Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3,” Journal of Neuroscience Research, vol. 86, no. 2, pp. 317–325, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. R. Simard and S. Rivest, “Do pathogen exposure and innate immunity cause brain diseases?” Neurological Research, vol. 27, no. 7, pp. 717–725, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. M. Ransohoff and V. H. Perry, “Microglial physiology: unique stimuli, specialized responses,” Annual Review of Immunology, vol. 27, pp. 119–145, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. G. C. Brown and J. J. Neher, “Inflammatory neurodegeneration and mechanisms of microglial killing of neurons,” Molecular Neurobiology, vol. 41, no. 2-3, pp. 242–247, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu, “Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients,” Neuroscience Letters, vol. 165, no. 1-2, pp. 208–210, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Arai, T. Furuya, T. Yasuda, M. Miura, Y. Mizuno, and H. Mochizuki, “Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1β, and expression of caspase-11 in mice,” Journal of Biological Chemistry, vol. 279, no. 49, pp. 51647–51653, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. W. M. Caudle and J. Zhang, “Glutamate, excitotoxicity, and programmed cell death in parkinson disease,” Experimental Neurology, vol. 220, no. 2, pp. 230–233, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. D. W. Choi, “Glutamate neurotoxicity and diseases of the nervous system,” Neuron, vol. 1, no. 8, pp. 623–634, 1988. View at Google Scholar · View at Scopus
  31. L. Thirumangalakudi, L. Yin, H. V. Rao, and P. Grammas, “IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons,” Journal of Alzheimer's Disease, vol. 11, no. 3, pp. 305–311, 2007. View at Google Scholar · View at Scopus
  32. D. A. Loeffler, A. J. DeMaggio, P. L. Juneau, M. K. Havaich, and P. A. LeWitt, “Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation,” Clinical Neuropharmacology, vol. 17, no. 4, pp. 370–379, 1994. View at Google Scholar · View at Scopus
  33. K. Imamura, N. Hishikawa, M. Sawada, T. Nagatsu, M. Yoshida, and Y. Hashizume, “Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains,” Acta Neuropathologica, vol. 106, no. 6, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. C. Barcia, V. De Pablos, V. Bautista-Hernández et al., “Increased plasma levels of TNF-α but not of IL1-β in MPTP-treated monkeys one year after the MPTP administration,” Parkinsonism and Related Disorders, vol. 11, no. 7, pp. 435–439, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. R. Sen and D. Baltimore, “Multiple nuclear factors interact with the immunoglobulin enhancer sequences,” Cell, vol. 46, no. 5, pp. 705–716, 1986. View at Google Scholar · View at Scopus
  36. R. Sen and D. Baltimore, “Inducibility of K immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism,” Cell, vol. 47, no. 6, pp. 921–928, 1986. View at Google Scholar · View at Scopus
  37. G. Tsoulfas and D. A. Geller, “NF-κB in transplantation: friend or foe?” Transplant Infectious Disease, vol. 3, no. 4, pp. 212–219, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. K. A. Roebuck, “Regulation of interleukin-8 gene expression,” Journal of Interferon and Cytokine Research, vol. 19, no. 5, pp. 429–438, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Xia, M. E. Pauza, L. Feng, and D. Lo, “RelB regulation of chemokine expression modulates local inflammation,” American Journal of Pathology, vol. 151, no. 2, pp. 375–387, 1997. View at Google Scholar · View at Scopus
  40. K. A. Roebuck, L. R. Carpenter, V. Lakshminarayanan, S. M. Page, J. N. Moy, and L. L. Thomas, “Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-κB,” Journal of Leukocyte Biology, vol. 65, no. 3, pp. 291–298, 1999. View at Google Scholar · View at Scopus
  41. T. Lawrence, “The nuclear factor NF-kappaB pathway in inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, article a001651, 2009. View at Google Scholar
  42. K. A. Gauss, L. K. Nelson-Overton, D. W. Siemsen, Y. Gao, F. R. DeLeo, and M. T. Quinn, “Role of NF-κB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-α,” Journal of Leukocyte Biology, vol. 82, no. 3, pp. 729–741, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. C. C. Chen and A. M. Manning, “Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-κB,” Agents and Actions Supplements, vol. 47, pp. 135–141, 1995. View at Google Scholar · View at Scopus
  44. P. P. Tak and G. S. Firestein, “NF-κB: a key role in inflammatory diseases,” Journal of Clinical Investigation, vol. 107, no. 1, pp. 7–11, 2001. View at Google Scholar · View at Scopus
  45. K. Van der Heiden, S. Cuhlmann, A. Luong, M. Zakkar, and P. C. Evans, “Role of nuclear factor kappaB in cardiovascular health and disease,” Clinical Science, vol. 118, no. 10, pp. 593–605, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. C. A. Latanich and L. H. Toledo-Pereyra, “Searching for NF-κB-based treatments of ischemia reperfusion injury,” Journal of Investigative Surgery, vol. 22, no. 4, pp. 301–315, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. K. Vandenbroeck, I. Alloza, M. Gadina, and P. Matthys, “Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges,” Journal of Pharmacy and Pharmacology, vol. 56, no. 2, pp. 145–160, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. L. A. Criswell, “Gene discovery in rheumatoid arthritis highlights the CD40/NF-κB signaling pathway in disease pathogenesis,” Immunological Reviews, vol. 233, no. 1, pp. 55–61, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. I. Atreya, R. Atreya, and M. F. Neurath, “NF-κB in inflammatory bowel disease,” Journal of Internal Medicine, vol. 263, no. 6, pp. 591–596, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. T. Lawrence and C. Fong, “The resolution of inflammation: anti-inflammatory roles for NF-κB,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 4, pp. 519–523, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. S. G. Pereira and F. Oakley, “Nuclear factor-κB1: regulation and function,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 8, pp. 1425–1430, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. M. S. Wang, S. Boddapati, S. Emadi, and M. R. Sierks, “Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model,” BMC Neuroscience, vol. 11, article 57, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. T. Huxford and G. Ghosh, “A structural guide to proteins of the NF-kappaB signaling module,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 3, article a000075, 2009. View at Google Scholar
  54. A. Oeckinghaus and S. Ghosh, “The NF-kappaB family of transcription factors and its regulation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 4, article a000034, 2009. View at Google Scholar
  55. M. J. May, R. B. Marienfeld, and S. Ghosh, “Characterization of the IκB-kinase NEMO binding domain,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 45992–46000, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. N. Sizemore et al., “Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B,” The Journal of Biological Chemistry, vol. 277, no. 6, pp. 3863–3869, 2002. View at Google Scholar
  57. N. Sizemore, A. Agarwal, K. Das et al., “Inhibitor of κB kinase is required to activate a subset of interferon γ-stimulated genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 7994–7998, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. J. Y. Reuther-Madrid, D. Kashatus, S. Chen et al., “The p65/RelA subunit of NF-κB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor,” Molecular and Cellular Biology, vol. 22, no. 23, pp. 8175–8183, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Rudolph, W. C. Yeh, A. Wakeham et al., “Severe liver degeneration and lack of NF-κB activation in NEMO/IKK γ- deficient mice,” Genes and Development, vol. 14, no. 7, pp. 854–862, 2000. View at Google Scholar · View at Scopus
  60. Z. P. Xia and Z. J. Chen, “TRAF2: a double-edged sword?” Science's STKE, vol. 2005, no. 272, p. e7, 2005. View at Google Scholar · View at Scopus
  61. M. Neumann and M. Naumann, “Beyond IκBs: alternative regulation of NF-κB activity,” FASEB Journal, vol. 21, no. 11, pp. 2642–2654, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. K. D. Brown, E. Claudio, and U. Siebenlist, “The roles of the classical and alternative nuclear factor-κB pathways: potential implications for autoimmunity and rheumatoid arthritis,” Arthritis Research and Therapy, vol. 10, no. 4, article 212, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. A. Israel, “The IKK complex, a central regulator of NF-kappaB activation,” Cold Spring Harbor Perspectives in Biology, vol. 2, no. 3, article a000158, 2010. View at Google Scholar
  64. N. Bakkar and D. C. Guttridge, “NF-κB signaling: a tale of two pathways in skeletal myogenesis,” Physiological Reviews, vol. 90, no. 2, pp. 495–511, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. J. L. Pomerantz and D. Baltimore, “Two pathways to NF-κB,” Molecular Cell, vol. 10, no. 4, pp. 693–695, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Yamamoto, U. N. Verma, S. Prajapati, K. Youn-Tae, and R. B. Gaynor, “Histone H3 phosphorylation by ikk-α is critical for cytokine-induced gene expression,” Nature, vol. 423, no. 6940, pp. 655–659, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. V. Anest, J. L. Hanson, P. C. Cogswell, K. A. Steinbrecher, B. D. Strahl, and A. S. Baldwin, “A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression,” Nature, vol. 423, no. 6940, pp. 659–663, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. A. K. Sil, S. Maeda, Y. Sono, D. B. Roop, and M. Karin, “IκB kinase-α acts in the epidermis to control skeletal and craniofacial morphogenesis,” Nature, vol. 428, no. 6983, pp. 660–664, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. R. Gareus, M. Huth, B. Breiden et al., “Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation,” Nature Cell Biology, vol. 9, no. 4, pp. 461–469, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. J. M. Dahlman, N. Bakkar, W. He, and D. C. Guttridge, “NF-κB functions in stromal fibroblasts to regulate early postnatal muscle development,” Journal of Biological Chemistry, vol. 285, no. 8, pp. 5479–5487, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. N. Bakkar, J. Wang, K. J. Ladner et al., “IKK/NF-κB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis,” Journal of Cell Biology, vol. 180, no. 4, pp. 787–802, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. Y. Xue, X. Wang, Z. Li, N. Gotoh, D. Chapman, and E. Y. Skolnik, “Mesodermal patterning defect in mice lacking the Ste20 NCK interacting kinase (NIK),” Development, vol. 128, no. 9, pp. 1559–1572, 2001. View at Google Scholar · View at Scopus
  73. N. S. Soysa, N. Alles, D. Weih et al., “The pivotal role of the alternative NF-κB pathway in maintenance of basal bone homeostasis and osteoclastogenesis,” Journal of Bone and Mineral Research, vol. 25, no. 4, pp. 809–818, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. M. Mogi, T. Kondo, Y. Mizuno, and T. Nagatsu, “p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain,” Neuroscience Letters, vol. 414, no. 1, pp. 94–97, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. S. Hunot, B. Brugg, D. Ricard et al., “Nuclear translocation of NF-κb is increased in dopaminergic neurons of patients with Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 14, pp. 7531–7536, 1997. View at Publisher · View at Google Scholar · View at Scopus
  76. J. P. Cao, H. J. Wang, J. K. Yu, H. M. Liu, and D. S. Gao, “The involvement of NF-κB p65/p52 in the effects of GDNF on DA neurons in early PD rats,” Brain Research Bulletin, vol. 76, no. 5, pp. 505–511, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. M. J. May, F. D'Acquisto, L. A. Madge, J. Glockner, J. S. Pober, and S. Ghosh, “Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex,” Science, vol. 289, no. 5484, pp. 1550–1554, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Di Meglio, A. Ianaro, and S. Ghosh, “Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation,” Arthritis and Rheumatism, vol. 52, no. 3, pp. 951–958, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. E. Jimi, K. Aoki, H. Saito et al., “Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo,” Nature Medicine, vol. 10, no. 6, pp. 617–624, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. S. Dai, T. Hirayama, S. Abbas, and Y. Abu-Amer, “The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis,” Journal of Biological Chemistry, vol. 279, no. 36, pp. 37219–37222, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. S. H. Davé, J. S. Tilstra, K. Matsuoka et al., “Amelioration of chronic murine colitis by peptide-mediated transduction of the IκB kinase inhibitor NEMO binding domain peptide,” Journal of Immunology, vol. 179, no. 11, pp. 7852–7859, 2007. View at Google Scholar · View at Scopus
  82. A. Desai, N. Singh, and R. Raghubir, “Neuroprotective potential of the NF-[kappa]B inhibitor peptide IKK-NBD in cerebral ischemia-reperfusion injury,” Neurochemistry International, vol. 57, no. 8, pp. 876–883, 2010. View at Google Scholar
  83. G. Grassia et al., “The I{kappa}B kinase inhibitor nuclear factor-{kappa}B essential modulator-binding domain peptide for inhibition of balloon injury-induced neointimal formation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2458–2466, 2010. View at Publisher · View at Google Scholar · View at PubMed
  84. N. C. Moss, W. E. Stansfield, M. S. Willis, R. H. Tang, and C. H. Selzman, “IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury,” American Journal of Physiology, vol. 293, no. 4, pp. H2248–H2253, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. F. Zhang, L. Qian, P. M. Flood, J. S. Shi, J. S. Hong, and H. M. Gao, “Inhibition of IκB kinase-β protects dopamine neurons against lipopolysaccharide-induced neurotoxicity,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 3, pp. 822–833, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. K. Ziegelbauer, F. Gantner, N. W. Lukacs et al., “A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and shows broad anti-inflammatory activity,” British Journal of Pharmacology, vol. 145, no. 2, pp. 178–192, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. T. Hideshima, D. Chauhan, P. Richardson et al., “NF-κB as a therapeutic target in multiple myeloma,” Journal of Biological Chemistry, vol. 277, no. 19, pp. 16639–16647, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. P. L. Podolin, J. F. Callahan, B. J. Bolognese et al., “Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 1, pp. 373–381, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. M. J. O'Shaughnessy, C. Vogtenhuber, K. Sun et al., “Ex vivo inhibition of NF-κB signaling in alloreactive T-cells prevents graft-versus-host disease,” American Journal of Transplantation, vol. 9, no. 3, pp. 452–462, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. T. Hideshima, T. Hayashi, D. Chauhan, M. Akiyama, P. Richardson, and K. Anderson, “Biologic sequelae of c-Jun NH-terminal kinase (JNK) activation in multiple myeloma cell lines,” Oncogene, vol. 22, no. 54, pp. 8797–8801, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. J. Yang et al., “Conditional ablation of Ikkb inhibits melanoma tumor development in mice,” The Journal of Clinical Investigation, vol. 120, no. 7, pp. 2563–2574, 2010. View at Google Scholar
  92. M. Schön, B. G. Wienrich, S. Kneitz et al., “KINK-1, a novel small-molecule inhibitor of IKKβ, and the susceptibility of melanoma cells to antitumoral treatment,” Journal of the National Cancer Institute, vol. 100, no. 12, pp. 862–875, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. K. Amschler, M. P. Schön, N. Pletz, K. Wallbrecht, L. Erpenbeck, and M. Schön, “NF-κB inhibition through proteasome inhibition or ikkβ blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways,” Journal of Investigative Dermatology, vol. 130, no. 4, pp. 1073–1086, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. A. Yemelyanov, A. Gasparian, P. Lindholm et al., “Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells,” Oncogene, vol. 25, no. 3, pp. 387–398, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. K. W. Moore, R. De Waal Malefyt, R. L. Coffman, and A. O'Garra, “Interleukin-10 and the interleukin-10 receptor,” Annual Review of Immunology, vol. 19, pp. 683–765, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. K. Strle, J. H. Zhou, W. H. Shen et al., “Interleukin-10 in the brain,” Critical Reviews in Immunology, vol. 21, no. 5, pp. 427–449, 2001. View at Google Scholar · View at Scopus
  97. Y. Zhu, G. Y. Yang, B. Ahlemeyer et al., “Transforming growth factor-β1 increases bad phosphorylation and protects neurons against damage,” Journal of Neuroscience, vol. 22, no. 10, pp. 3898–3909, 2002. View at Google Scholar · View at Scopus
  98. M. Szczepanik, M. Tutaj, K. Bryniarski, and B. N. Dittel, “Epicutaneously induced TGF-β-dependent tolerance inhibits experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 164, no. 1-2, pp. 105–114, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. W. Zhang, J. S. Hong, H. C. Kim, W. Zhang, and M. L. Block, “Morphinan neuroprotection: new insight into the therapy of neurodegeneration,” Critical Reviews in Neurobiology, vol. 16, no. 4, pp. 271–302, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Qian et al., “NADPH oxidase inhibitor DPI is neuroprotective at femtomolar concentrations through inhibition of microglia over-activation,” Parkinsonism and Related Disorders, vol. 13, supplement 3, pp. S316–S320, 2007. View at Google Scholar
  101. L. Qian, P. M. Flood, and J. S. Hong, “Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy,” Journal of Neural Transmission, vol. 117, no. 8, pp. 971–979, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. S. Yang, D. Zhang, Z. Yang et al., “Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture,” Neurochemical Research, vol. 33, no. 10, pp. 2044–2053, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. L. Qian, H. -M. Wu, S. -H. Chen et al., “β2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway,” Journal of Immunology, vol. 186, no. 7, pp. 4443–4454, 2011. View at Google Scholar
  104. A. Ghosh, A. Roy, X. Liu et al., “Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18754–18759, 2007. View at Publisher · View at Google Scholar · View at PubMed
  105. F. Zhang, L. Qian, P. M. Flood, J. S. Shi, J. S. Hong, and H. M. Gao, “Inhibition of IκB kinase-β protects dopamine neurons against lipopolysaccharide-induced neurotoxicity,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 3, pp. 822–833, 2010. View at Publisher · View at Google Scholar · View at PubMed